The global ovarian germ cell tumor (OGCT) market is driven by the rising prevalence of these tumors, which account for approximately 2-5% of all ovarian cancers. Ovarian germ cell tumors predominantly affect women during their reproductive years, with a peak incidence observed in adolescents and young adults aged 15-25 years. Studies indicate that the annual incidence rate of ovarian germ cell tumors is around 1 to 2 cases per 1 million women worldwide. In terms of geographic distribution, the highest prevalence is reported in North America and Europe, with notable differences in diagnosis and treatment outcomes across regions. The increasing awareness of early detection and advancements in diagnostic technologies are improving survival rates, with 5-year survival rates exceeding 90% for early-stage tumors. However, challenges remain in treating advanced and recurrent cases, highlighting the need for continued research and the development of more effective therapies.
